am -
pm ET

The Team

Alnylam Assist™ is comprised of dedicated, passionate individuals with diverse backgrounds and expertise in patient support. If you've decided to prescribe an Alnylam therapy to your patient, you can complete a Start Form and contact a Case Manager if you have any questions.

Alnylam Assist® Case Managers

Case Managers

Alnylam Assist™ is committed to the patient experience of those who start treatment with OXLUMO® (lumasiran). Patients are partnered with a Case Manager in their local area. Case Managers are trained professionals whose expertise is in helping patients get started on treatment and providing product support including:

Insurance benefit verification and connecting with a Field Reimbursement Director

Financial assistance enrollment for eligible patients*

Help ordering product

Connecting patients with a Patient Education Liaison (PEL)

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

Alnylam Assist® Case Manager Kevin

Your Local Case Manager, Kevin

Alnylam Assist® Patient Education Liasons

Patient Education Liaisons

Patient Education Liaisons (PELs) are professionals with backgrounds in nursing who are experienced in educating patients and their families. PELs support patients and their families in a number of ways:

Engaging patients and families with educational resources

Answering questions about PH1 and treatment

Providing customized education, including one-on-one education or family meetings

The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers

PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice

All diagnosis and treatment decisions should be made by the treating physician and their patients

Alnylam Assist® Field Reimbursement Directors

Field Reimbursement Directors

Field Reimbursement Directors (FRDs) are experienced professionals who provide education on the reimbursement process. They provide education to the patient's health care team on:

OXLUMO billing and coding requirements

Payer requirements for OXLUMO® coverage

Payer issue identification and resolution

Support throughout the Treatment Process

Alnylam Assist® Enrollment Process - Step 1: Complete Start Form. Step 2: Case Manager Reaches Out. Step 3: Patient Support Provided

Alnylam Assist® Enrollment Process - Step 1: Complete Start Form. Step 2: Case Manager Reaches Out. Step 3: Patient Support Provided

What is the enrollment process for the Alnylam Assist™ program?

Everything you need to know about the enrollment process and its requirements, including what your patients need to know, can be found on this site. View the enrollment process ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

Enrolling Your Patients

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›


Alnylam Assist® Start Form - To Print And Fax

& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle


Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.


OXLUMO® (lumasiran) is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.